Latest: Eli Lilly announced 7 Phase 3 readouts expected throughout 2026. FDA submission anticipated by late 2026/early 2027.
The Timeline: When Will Retatrutide Be Available?
Phase 3 Clinical Trials: The TRIUMPH Program
Eli Lilly's Phase 3 program for retatrutide is called TRIUMPH (Triple Hormone Receptor Agonist in Patients with Obesity). Here's what we know:
First Phase 3 to report. Showed retatrutide's efficacy and safety in people with obesity and joint pain. Bonus: significant reduction in osteoarthritis symptoms.
Testing retatrutide in people with obesity but no major health conditions. This will be the "core" weight loss trial for FDA approval.
Additional trials test retatrutide in people with type 2 diabetes, heart disease risk, fatty liver disease, and other obesity-related conditions.
What Could Delay or Accelerate Approval?
Factors That Could Speed Up Approval
- Priority Review: FDA can grant 6-month review (vs 10-month standard) for significant advancements. Retatrutide's superior efficacy may qualify.
- Clean Safety Data: If Phase 3 shows minimal serious adverse events, FDA may fast-track.
- Obesity Crisis: Political/public health pressure to approve effective obesity medications quickly.
- Early FDA Engagement: Eli Lilly likely discussing retatrutide with FDA throughout trials, reducing surprises.
Factors That Could Delay Approval
- Safety Signals: If rare serious side effects emerge in Phase 3, FDA will request more data.
- Manufacturing Issues: Drug shortages (like tirzepatide/semaglutide) could delay launch even after approval.
- Additional Studies Requested: FDA may want longer-term safety data or specific sub-population studies.
- Regulatory Backlog: FDA review times can vary based on workload.
Will There Be a Clinical Trial I Can Join?
Possibly, but trials are filling fast. Search ClinicalTrials.gov for "retatrutide" to find open trials.
Typical eligibility criteria:
- BMI ≥30 (or ≥27 with weight-related health condition)
- Age 18-75
- No current use of other weight loss medications
- No history of pancreatitis, thyroid cancer, or certain GI disorders
Benefits of trial participation: Free medication, close medical monitoring, contribution to science. Downside: You may be randomized to placebo (though crossover is common).
What to Do While Waiting for Retatrutide
Don't wait 1-2 years to start your weight loss journey. Here's what you should do now:
- Start tirzepatide (available now): Delivers 15-22.5% weight loss—excellent results while you wait for retatrutide. You can switch later if you want even more weight loss.
- Sign up for retatrutide updates: Get notified the moment FDA approves and providers start offering it.
- Build healthy habits now: Combining medication with diet/exercise improvements maximizes results.
📧 Get Notified When Retatrutide Is FDA Approved
Join the waitlist. We'll email you the day retatrutide becomes available through telemedicine providers.
Projected Market Impact
Industry analysts predict retatrutide will be a blockbuster drug with massive commercial impact:
- Projected sales: $15.6 billion by 2031 (GlobalData estimate)
- Market share: Expected to capture 30-40% of the GLP-1 weight loss market
- Impact on competitors: Tirzepatide and semaglutide sales may plateau as patients switch to retatrutide
- Pricing: Expect $900-1,400/month initially (matching current GLP-1 pricing)
The Bottom Line
Best Case Scenario: FDA approval by late 2027, availability by early 2028
Most Likely Scenario: FDA approval by Q1-Q2 2028, availability by mid-late 2028
What You Should Do: Start tirzepatide NOW ($179-499/month through telemedicine), then switch to retatrutide when it's approved if you want even better results.
Related Reading:
- What Is Retatrutide? Complete Guide to the Triple Agonist Peptide
- Retatrutide vs Tirzepatide: Which Is Better for Weight Loss?
- How to Get Tirzepatide Without Insurance (2026)